Gastrointestinal complications — particularly intestinal obstruction, pancreatitis, and gastroparesis — are sending thousands of GLP-1 drug users to emergency rooms every year. A study published in JAMA found that patients taking semaglutide (Ozempic, Wegovy) and similar drugs face a 9.09 times higher risk of pancreatitis, a 4.22 times higher risk of intestinal obstruction, and a 3.67 times higher risk of gastroparesis compared to people on other weight-loss medications. These are not minor inconveniences. Intestinal obstruction can be fatal without emergency surgery. Gastroparesis — where the stomach essentially becomes paralyzed — can leave patients unable to eat for weeks. And pancreatitis, an acute inflammation of the pancreas, has been linked to at least 19 deaths in the UK alone.
The scale of the problem is growing in lockstep with the drugs’ popularity. One in eight American adults has now tried a GLP-1 medication, and prescriptions have more than tripled since 2020. Total prescriptions for Ozempic and Wegovy increased almost 3,000 percent between 2018 and 2022. As Dr. Caroline Apovian of Brigham and Women’s Hospital has observed, “Patients didn’t want to complain because they were losing weight, and they wound up in the ER with extreme constipation or a small bowel obstruction.” For readers of this site concerned about brain health and dementia caregiving, the implications are personal — many GLP-1 users fall into the demographic most affected by cognitive decline, and emergency hospitalizations carry their own serious risks for older adults. This article breaks down the specific side effects driving ER visits, what the FDA has done in response, the rising wave of lawsuits, and what anyone taking or considering these drugs should know before filling a prescription.
Table of Contents
- Which GLP-1 Drug Side Effects Are Sending Thousands to the ER?
- Why Older Adults and Dementia Caregivers Should Pay Close Attention
- The FDA’s Response and Label Changes
- How to Reduce Your Risk While Taking GLP-1 Medications
- The Legal Landscape and What It Signals About Long-Term Risk
- Off-Label Use and the Unknowns That Should Worry Everyone
- What Comes Next for GLP-1 Safety Monitoring
- Conclusion
- Frequently Asked Questions
Which GLP-1 Drug Side Effects Are Sending Thousands to the ER?
The most dangerous side effects fall into three categories: intestinal obstruction, pancreatitis, and gastroparesis. Intestinal obstruction — also called ileus — occurs when the bowel becomes blocked, preventing food and waste from passing through. According to the WHO’s VigiBase adverse drug reaction database, intestinal obstructions are reported 4.5 times more frequently with GLP-1 drugs than with other diabetes medications. This is not a side effect that resolves on its own. Many patients require emergency surgery, and delays in treatment can be fatal. The JAMA study put the risk at 4.22 times higher than what is seen with other weight-loss drugs, and research shows the risk actually increases over time, with the highest rates occurring around 1.6 years after starting treatment. Pancreatitis is another leading driver of ER visits. A population-based case-control study examining 1,269 hospitalized pancreatitis cases found that GLP-1 users were over twice as likely to develop the condition, with an adjusted odds ratio of 2.24 within 30 days of drug exposure.
The UK has recorded 19 deaths and nearly 1,300 reports of pancreatitis associated with GLP-1 drugs between 2007 and October 2025. Brazil reported 6 deaths and 145 cases from 2020 to December 2025. Clinical trial data from the STEP programme puts the rate at roughly 0.2 cases per 100 patient-years — uncommon by clinical standards, but when tens of millions of people are taking the drug, the absolute numbers become significant. Then there are the more “common” gastrointestinal side effects that, in severe cases, also lead to hospitalization. Nausea affects 15 to 50 percent of users. Vomiting hits 5 to 20 percent. Constipation affects 4 to 12 percent. For most people these are manageable annoyances, but severe constipation can progress to fecal impaction, which itself can require emergency intervention. Gastroparesis — stomach paralysis — sits at the more extreme end of this spectrum and can make it impossible for a patient to eat normally for extended periods.
Why Older Adults and Dementia Caregivers Should Pay Close Attention
For readers focused on brain health and dementia care, the risks of GLP-1-related hospitalizations carry an extra dimension that rarely gets discussed. Emergency room visits and surgeries are independently associated with cognitive decline in older adults. Anesthesia, hospital-acquired infections, delirium, and the disruption of daily routines can accelerate cognitive deterioration in someone already living with mild cognitive impairment or early-stage dementia. A bowel obstruction requiring emergency surgery is not just a gastrointestinal crisis — for a 70-year-old with memory concerns, it can be a turning point. Women aged 50 to 64 have the highest GLP-1 use rate at 20 percent — one in five. This is the same demographic that often serves as primary caregivers for aging parents with dementia and that is beginning to face its own cognitive health questions.
However, it is worth noting that some early research has suggested GLP-1 drugs may have neuroprotective properties and could potentially reduce dementia risk. This creates a genuine tension: the same class of drugs that might offer long-term brain benefits can also cause short-term medical emergencies that are particularly dangerous for older adults. Anyone in this position should weigh these tradeoffs carefully with their physician rather than assuming the weight-loss benefits automatically outweigh the risks. If you are a caregiver for someone with dementia who is also taking a GLP-1 medication, watch closely for signs of severe constipation, abdominal pain, persistent vomiting, or sudden loss of appetite. These can be early warnings of gastroparesis or intestinal obstruction, and a person with cognitive impairment may not be able to articulate what they are feeling.
The FDA’s Response and Label Changes
The FDA has responded to the growing body of adverse event data, though critics argue the agency has been slow. In September 2023, the FDA updated Ozempic’s label to add ileus — a form of intestinal obstruction — as a possible side effect. By late 2025, the label was updated again to include intestinal obstruction and severe constipation with fecal impaction. These additions came after years of post-market adverse event reports and mounting pressure from gastroenterologists and patient advocates. As of April 30, 2025, the FDA had received 520 adverse event reports for compounded semaglutide and 480 for compounded tirzepatide. A disturbing finding in many of these reports: patients were accidentally taking 5 to 20 times their intended dose due to errors with compounded formulations.
This is a specific and avoidable danger. Compounded GLP-1 drugs — versions made by specialty pharmacies rather than the brand-name manufacturers — skip the FDA review process for safety and quality. The FDA has explicitly flagged these products as posing additional risks, and multiple hospitalizations have been tied directly to dosing errors with compounded injectables. California hospital data from 2018 to 2022 offers a window into the broader trend. During this period of rapid GLP-1 adoption, gallbladder inflammation encounters surged 492 percent. Acute kidney injury hospital encounters rose 18 percent, and hypoglycemia cases increased 27 percent. Correlation is not causation, and other factors could contribute to these increases, but the timing aligns closely with the explosion in GLP-1 prescriptions.
How to Reduce Your Risk While Taking GLP-1 Medications
The first and most important step is to use only FDA-approved versions of these medications — not compounded alternatives from online pharmacies or telehealth startups offering suspiciously low prices. The dosing errors associated with compounded drugs are not theoretical risks; they are documented causes of hospitalization. The cost difference between brand-name and compounded versions can be substantial, but so is the difference between a controlled dose and one that is 20 times too high. Second, the dose escalation schedule matters. GLP-1 drugs are designed to be started at a low dose and increased gradually over weeks or months. Rushing this process — whether because of impatience for weight loss or because a provider is not following established protocols — significantly increases the likelihood of severe gastrointestinal side effects.
If nausea, vomiting, or constipation become severe at any dose level, that is a signal to pause the escalation and talk to your prescriber, not to push through it. The tradeoff is straightforward: slower dose increases mean slower weight loss but a much lower chance of ending up in the ER. Third, be aware that the risk of certain complications, particularly intestinal obstruction, increases with duration of use. Research indicates the highest rates occur around 1.6 years after starting treatment. This means that even if you tolerate the first several months without problems, ongoing vigilance is necessary. Regular check-ins with your physician, reporting any new digestive symptoms promptly, and understanding the warning signs of bowel obstruction — severe abdominal pain, inability to pass gas or stool, persistent vomiting — are not optional.
The Legal Landscape and What It Signals About Long-Term Risk
Thousands of lawsuits have been consolidated in MDL No. 3094 in the Eastern District of Pennsylvania, targeting Novo Nordisk (maker of Ozempic and Wegovy) and Eli Lilly (maker of Mounjaro and Zepbound). The breakdown of federal claims is telling: 75 percent allege gastroparesis, 18 percent allege ileus, 18 percent allege intestinal obstruction, and 8 percent allege gallbladder injuries. These are not frivolous claims about mild nausea. These are people who say they suffered serious, life-altering medical complications. The lawsuits collectively argue that the manufacturers failed to adequately warn patients and prescribers about the severity and frequency of gastrointestinal side effects.
The fact that the FDA updated Ozempic’s label multiple times after initial approval supports the claim that the original warnings were insufficient. However, it is important to understand that the existence of lawsuits does not prove the drugs are unsafe for everyone — it proves that some patients experienced outcomes that were not adequately disclosed. The legal process will take years to resolve, and in the meantime, the drugs remain on the market and continue to be prescribed to millions. Both the UK and Brazil have issued formal warnings about the pancreatitis link, adding international regulatory weight to the concern. For patients and caregivers, the practical takeaway is this: do not rely solely on your prescriber’s initial counseling about side effects. Read the current FDA label yourself. The warnings have changed multiple times, and what your doctor told you in 2023 may no longer reflect the full picture.
Off-Label Use and the Unknowns That Should Worry Everyone
A significant portion of GLP-1 prescriptions are written off-label — for weight loss in people without diabetes, which is the condition these drugs were originally developed to treat. Researchers have warned that if large numbers of non-diabetic people continue off-label use, delayed adverse effects could become a major public health issue. The clinical trials that established the safety profile of these drugs studied specific populations over specific timeframes.
What happens when healthy 35-year-olds take them for five or ten years is genuinely unknown. This matters especially for the brain health community because some of the most promising GLP-1 research involves potential applications for Alzheimer’s disease and neurodegeneration. If these drugs do eventually prove useful for dementia prevention, understanding their full side effect profile becomes even more critical. A drug taken for a few years to lose weight has a different risk calculus than one taken for decades to protect cognitive function.
What Comes Next for GLP-1 Safety Monitoring
The next several years will be decisive. As the first large cohorts of long-term GLP-1 users pass the two-year, five-year, and ten-year marks, we will have far better data on delayed complications. The MDL lawsuits will also produce discovery documents and expert testimony that may reveal what manufacturers knew and when they knew it. Meanwhile, newer GLP-1 formulations and combination drugs are entering the market, each with their own side effect profiles that have yet to be tested at population scale.
For now, the responsible position is neither to panic nor to dismiss the risks. These drugs offer real benefits for many people — meaningful weight loss, improved blood sugar control, and potentially reduced cardiovascular risk. But the gastrointestinal complications are also real, they are sending thousands of people to emergency rooms, and the long-term consequences remain understudied. Anyone taking or considering a GLP-1 medication deserves honest information about both sides of that equation.
Conclusion
GLP-1 drugs like Ozempic, Wegovy, and Mounjaro have transformed weight management and diabetes care for millions of Americans, but the surge in ER visits for intestinal obstruction, pancreatitis, and gastroparesis is a serious and growing concern. The numbers are not ambiguous: a 9-fold increase in pancreatitis risk, a 4-fold increase in intestinal obstruction, nearly 1,300 pancreatitis reports in the UK alone, and a 492 percent increase in gallbladder inflammation encounters in California hospitals during the period of rapid adoption. The FDA has responded with multiple label updates, but much of this information arrived years after millions of prescriptions had already been written.
For anyone in the dementia care and brain health community, these risks carry added weight. Emergency hospitalizations, surgeries, and their aftereffects can be especially damaging for older adults and those with cognitive vulnerabilities. If you or someone you care for is taking a GLP-1 medication, use only FDA-approved versions, follow the prescribed dose escalation schedule, report any gastrointestinal symptoms promptly, and stay current on label changes. The conversation about these drugs is still evolving, and staying informed is not just advisable — it is a form of self-protection.
Frequently Asked Questions
What is the most common GLP-1 side effect that leads to ER visits?
Gastrointestinal complications are the primary driver. Intestinal obstruction (ileus), pancreatitis, and gastroparesis (stomach paralysis) are the most serious, while severe constipation and vomiting also account for emergency visits. A JAMA study found GLP-1 users face a 9.09 times higher risk of pancreatitis and a 4.22 times higher risk of intestinal obstruction compared to those on other weight-loss drugs.
Are compounded GLP-1 drugs more dangerous than brand-name versions?
Yes. Compounded versions skip FDA review for safety and quality, and the FDA has documented cases where patients accidentally took 5 to 20 times their intended dose. As of April 2025, the FDA received 520 adverse event reports for compounded semaglutide and 480 for compounded tirzepatide. Stick with FDA-approved formulations prescribed through a licensed provider.
Does the risk of side effects increase the longer you take GLP-1 drugs?
For some complications, yes. Research shows the risk of intestinal obstruction is highest at approximately 1.6 years after starting GLP-1 drugs. This means patients who tolerate the drugs well initially should not assume they are out of the woods and should continue monitoring for symptoms.
Can GLP-1 drugs affect people with dementia or cognitive impairment?
While some research suggests GLP-1 drugs may have neuroprotective properties, the serious side effects — particularly those requiring hospitalization or surgery — pose real dangers for people with cognitive impairment. Hospitalization, anesthesia, and delirium are known accelerators of cognitive decline in older adults. Caregivers should closely monitor for abdominal pain, vomiting, and changes in bowel habits.
Who is most likely to be taking GLP-1 drugs?
Women aged 50 to 64 have the highest use rate at 20 percent. Overall, about 1 in 8 US adults has tried a GLP-1 medication as of 2025, and prescriptions have more than tripled since 2020.
Are there lawsuits related to GLP-1 drug side effects?
Yes. Thousands of lawsuits have been consolidated in MDL No. 3094 in the Eastern District of Pennsylvania against Novo Nordisk and Eli Lilly. Among federal claims, 75 percent allege gastroparesis, 18 percent allege ileus or intestinal obstruction, and 8 percent allege gallbladder injuries.
